Healthcare & Life Sciences
Stemcentrx
United States
acquiredacquired
acquired
Stage
1
Investors
About
Stemcentrx developed precision therapies and diagnostics targeting cancer stem cells in solid tumors using a stem cell–centric discovery approach, focusing on oncology drug discovery until its acquisition by AbbVie in 2016.
Explore Stemcentrx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.